北方華創(002371.SZ):擬協議受讓先進製造持有的芯源微9.49%股份
格隆匯3月10日丨北方華創(002371.SZ)公佈,為加快推動北方華創戰略落實,發揮協同效應,提高股東回報,公司以現金為對價,協議受讓先進製造持有的芯源微9.49%股份,合計19,064,915股,受讓價格為88.48元/股,交易金額約為16.87億元。
此外,瀋陽中科天盛自動化技術有限公司(簡稱“中科天盛”)持有瀋陽芯源微電子設備股份有限公司(股票代碼:688037,簡稱“芯源微”)8.41%股份,合計16,899,750股。中科天盛擬通過公開徵集轉讓方式協議轉讓所持芯源微的全部股份,公司將積極通過參與公開掛牌競買等方式繼續增持芯源微股份並取得對其控制權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.